Leukocyte filtration and aprotinin: Synergistic anti-inflammatory protection

Perfusion

Volumn 19, Issue SUPPL. 1, 2004, Pages

  Olivencia Yurvati, Albert H ^a   Wallace, Neil ^a   Ford, Sheila ^a   Mallet, Robert T ^b  

^a University of North Texas Health Science Center   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; FREE RADICAL;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOPULMONARY BYPASS; CELL PROTECTION; CELL SEPARATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG MECHANISM; DRUG POTENTIATION; EXTRACORPOREAL CIRCULATION; FEMALE; FREQUENCY ANALYSIS; GAS EXCHANGE; HEART ATRIUM FIBRILLATION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ACTIVATION; LEUKOPENIA; LUNG ARTERIOVENOUS SHUNT; LUNG DISEASE; MALE; MOLECULAR MECHANICS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 2342555174     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659104pf714oa     Document Type: Article

References (41)

1. Wechsler AS. Editor's note. J Thorac Cardiovasc Surg 2003; 125: 983.
2. Kirklin JW, Donald DE, Harshbarger HG et al. Studies in extracorporeal circulation. I. Applicability of Gibbon-type pump-oxygenator to human intracardiac surgery: 40 cases. Ann Surg 1956; 144: 2-8.
3. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001; 71: 745-54.
4. Bull DA, Maurer J. Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 2003; 75: S735-39.
5. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 355-66.
6. Taylor KM. SIRS - the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61: 1607-8.
7. Gourlay T, Fleming J, Taylor KM. The effects of pulsatile flow on the leukocyte depleting qualities of the Pall LG6 leukocyte depleting arterial line filter: a laboratory investigation. Perfusion 1992; 7: 227-32.
8. Mayr A, Knotzer H, Pajk W et al. Risk factors associated with new onset tachyarrhythmias after cardiac surgery - a retrospective analysis. Acta Anaesthesiol Scand 2002; 45: 543-49.
9. Olivencia-Yurvati AH, Blair JL, Baig M, Mallet RT. Pyruvate-enhanced cardioprotection during cardiopulmonary bypass surgery. J Cardiothorac Vasc Anesth, 2003; 17: 175-20.
10. Ortolano G, Aldea GS, Lilly K et al. A review of leukofiltration in cardiac surgery: the time course of reperfusion injury may facilitate study design of anti-inflammatory effects. Perfusion 2002; 17: 53-62.
11. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002; 21: 232-44.
12. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715-20.
13. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg 1998; 66: 2135-44.
14. Stamou SC, Pfister AJ, Dangas G et al. Beating heart versus conventional single-vessel reoperative coronary artery bypass. Ann Thorac Surg 2000; 72: 977-78.
15. Ascione R, Caputo M, Calori G, Lloyd CT, Underwood MJ, Angelini GD. Predictors of atrial fibrillation after conventional and beating heart coronary surgery. Circulation 2000; 102: 1530-35.
16. Hernandez F, Cohn WE, Baribeau YR et al, Northern New England Cardiovascular Disease Study Group. In-hospital outcomes of off-pump versus on-pump coronary artery bypass procedures: a multicenter experience. Ann Thorac Surg 2001; 72: 1528-33.
17. Zamvar VY, Khan NU, Madhavan A, Kulatilake N, Butchart EG. Clinical outcomes in coronary artery bypass graft surgery: comparison of off-pump and on-pump techniques. Heart Surg Forum 2002; 5: 109-13.
18. Lancey RA, Soller BR, Vander Salm TJ. Off-pump versus on-pump coronary artery bypass surgery: a case-matched comparison of clinical outcomes and costs. Heart Surg Forum 2000; 3: 277-81.
19. Siebert J, Anisimowicz L, Lango R et al. Atrial fibrillation after coronary artery bypass grafting: does the type of procedure influence the early postoperative incidence? Eur J Cardiothorac Surg 2001; 19: 455-59.
20. Place DG, Peragallo RA, Carroll J, Cusimano RJ, Cheng DC. Postoperative atrial fibrillation: a comparison of off-pump coronary artery bypass surgery and conventional coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002; 16: 144-48.
21. Salamon T, Michler RE, Knott KM, Brown DA. Off-pump coronary artery bypass grafting does not decrease the incidence of atrial fibrillation. Ann Thorac Surg 2003; 75: 505-7.
22. Asimakopoulos G. The inflammatory response to CPB: the role of leukocyte filtration. Perfusion 2002; 17: 7-10.
23. Gu YJ, de Vries AJ, Boonstra PW, van Oeveren W. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. J Thorac Cardiovasc Surg 1996; 112: 494-500.
24. Royston D. Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharmacol 1996; 27: S42-S49.
25. Murkin JM. Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors? J Cardiothorac Vasc Anesth 1997; 11: 19-23.
26. McCarthy RJ, Tuman KJ, O'Connor C, Ivankovich AD. Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs. Anesth Analg 1999; 89: 1096-100.
27. +-exchange inhibition and aprotinin administration: promising tools for myocardial protection during minimally invasive CABG. Eur J Cardiothorac Surg 2001; 19: 633-39.
28. Wippermann CF, Schmid FX, Eberle B et al. Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. Ann Thorac Surg 1999; 67: 173-6.
29. Wendel HP, Heller W, Michel J et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 1995; 109: 1164-72.
30. Rahman A, Üstünda B, Burma O, Özercan IH, Çekirdekçi A, Bayar MK. Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass? Eur J Cardiothorac Surg 2000; 18: 583-88.
31. Traysol® package insert. Bayer Corporation Pharmaceutical Division, West Haven, CT, USA.
32. Gott JP. Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation. Perfusion 2001; 16: 5-9.
33. Olivencia-Yurvati AH, Wallace WE, Wallace N et al. Intraoperative treatment strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation. Perfusion 2002; 17: 35-39.
34. Olivencia-Yurvati AH, Ferrara CA, Tierney N, Wallace N, Mallet RT. Strategic leukocyte depletion reduces pulmonary microvascular pressure and improves pulmonary status post-cardiopulmonary bypass. Perfusion 2003; 18: 23-31.
35. Gu YJ, Mariani MA, Boonstra PW, Grandjean JG, van Oeveren W. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass. Chest 1999; 116: 892-8.
36. Penttilä HJ, Lepojärvi MVK, Kaukoranta PK, Kiviluoma KT, Ylitalo KV, Peuhkurinen KJ. Myocardial metabolism and hemodynamics during coronary surgery without cardiopulmonary bypass. Ann Thorac Surg 1999; 67: 683-88.
37. Hravnak M, Hoffman LA, Saul MI et al. Atrial fibrillation: prevalence after minimally invasive direct and standard coronary artery bypass. Ann Thorac Surg 2001; 71: 1491-95.
38. Saatvedt K, Fiane AE, Sellevold O, Nordstrand K. Is atrial fibrillation caused by extracorporeal circulation? Ann Thorac Surg 1999; 68: 931-3.
39. Kochamba GS, Yun KL, Pfeffer TA, Sintek CF, Khonsari S. Pulmonary abnormalities after coronary arterial bypass grafting operation: cardiopulmonary bypass versus mechanical stabilization. Ann Thorac Surg 2000; 69: 1466-70.
40. Courtney JM, Zhao XB, Qian H, Sharma A. Modification of polymer surfaces: optimization of approaches. Perfusion 2003; 18: 33-39.
41. Vijay V, McCusker K. Recent advances in biocompatible surface-modifying additives for cardiopulmonary bypass. Perfusion 2003; 18: 41-45.